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Background
Since it is the site of initial immune activation and
priming of antigen-specific T cells, as well as the first
location to which tumor cells metastasize, our research
focuses on understanding the immune status and
tumor-induced suppression within breast cancer (BrCa)-
draining sentinel lymph nodes (SLN).
Methods
Suppressive immune subsets were profiled by multi-color
flow cytometry in two different BrCa SLN cohorts. In the
first cohort, collected at the Providence Cancer Center
(08/11-07/13), we looked at frequencies of HLA-DR-
CD14+ myeloid cells and their expression of co-stimula-
tory and inhibitory receptors. Four metastasis+ SLN and
11 metastasis- SLN were assessed in this cohort. SLN in
the second cohort were collected at the VUmc in Amster-
dam and Kennemer Gasthuis in Haarlem (10/13-06/14)
and contained 2 metastasis+ and 7 metastasis- SLN. In
this cohort the frequencies of HLA-DR- CD14+ cells as
well as CD25_hi FoxP3+ T regulatory cells (Treg) were
analyzed. Since all tumors corresponding to the metastasis
+ SLN turned out to be HER2 negative, only metastasis-
SLN from HER2- tumors were included. Apart from 2
tumors in the Providence cohort, all tumors did express
progesterone and/or estrogen receptors.
Results
Elevated frequencies of HLA-DR- CD14+ immature
myeloid cells could be detected in the metastasis+ SLN
in both cohorts. This difference was statistically signifi-
cant for the Providence cohort (p < 0.0001) (3.8 fold
increase). No differences were observed for expression
levels of the co-stimulatory molecules CD80 and CD86
or the inhibitory molecules PD-L1 and B7H4 on HLA-
DR- CD14+ cells between positive or negative SLN and
expression was low for all these markers. Due to the
small number of metastasis+ SLN in the Dutch cohort
statistics could not yet be performed, but a 2.3 fold
increase in HLA-DR- CD14+ cells was seen. In this
cohort, frequencies of Treg were found to be 4-fold
higher in the metastasis+ SLN compared to metastasis-
SLN (0.31 ± 0.22 vs. 1.22 ± 0.24 Treg of CD4 T cells).
Moreover, a significant correlation was observed
between the frequencies of HLA-DR- CD14+ immature
myeloid cells and the frequencies of Treg in these BrCa
SLN (r = 0.718, p < 0.01).
Conclusion
Our data suggest that tumor-derived factors negatively
influence both the myeloid and the lymphoid compart-
ments within SLN draining HER2 negative breast cancers.
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